NCT03178149
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
At risk: Primary completion moved at least 1 year 6 months later.
See at-risk trials from Astellas Institute for Regenerative Medicine
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 49 versions: 42 with changes below, 7 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Start date pushed from Jul 13, 2018 to Jan 30, 2019
- Eligibility criteria shortened, about 22 words
- Secondary endpoints: details revised at 12 of 12 entries
- Site details revised at 2 of 20 sites
- Notable Primary and study completion pushed from Jun 30, 2026 to Dec 31, 2027
- Study sites: 19 to 20
- Minor Study sites: 18 to 19v47
- Minor Site details revised at 1 of 18 sitesv46
- Minor Study sites: 17 to 18v45
Show 36 earlier versionsHide 36 earlier versions
- Minor Study sites: 16 to 17v44
- Minor Site details revised at 1 of 16 sitesv43
- Minor Study sites: 15 to 16v42
- Notable Eligibility criteria revisedv41
- Minor Study sites: 14 to 15v40
- Notable Eligibility criteria shortened, about 133 words
- Secondary endpoints: 11 to 12
- Minor Primary and study completion dates: Jan 31, 2026 to Jun 30, 2026v38
- Study Status, Eligibility, IPDSharingv37
- Notable Eligibility criteria expanded, about 4 words
- Study sites: 12 to 14
- Minor Primary and study completion dates: Dec 31, 2025 to Jan 31, 2026v35
Notable Enrollment target: 18 to 42v34 Show 6 more changesShow less
- Primary and study completion dates: Aug 31, 2024 to Dec 31, 2025
- Eligibility criteria expanded, about 257 words
- Interventions: ASP7317 (Drug), tacrolimus (Drug) to ASP7317 (Drug), Acyclovir (Drug), Nystatin (Drug), tacrolimus (Drug), trimethoprim-sulfamethoxazole (Drug)
- Secondary endpoints: 4 to 11
- Study description revised
- Study title expanded, about 1 word
- Minor Site details revised at 1 of 12 sitesv33
- Minor Site details revised at 1 of 12 sitesv32
- Minor Site details revised at 1 of 12 sitesv30
- Minor Study sites: 11 to 12v29
- Minor Site details revised at 1 of 11 sitesv28
- Notable Trial status: Active, Not Recruiting to Recruiting
- Primary and study completion dates: Nov 30, 2022 to Aug 31, 2024
- Study sites: 6 to 11
- Study description shortened, about 11 words
- Minor Primary and study completion dates: Nov 2022 to Nov 30, 2022
- Study description expanded, about 2 words
Notable Phase: Phase 1/2 to Phase 1v22 Show 10 more changesShow less
- Enrollment target: 150 to 18
- Primary and study completion dates: Jan 2027 to Nov 2022
- Eligibility criteria shortened, about 92 words
- Primary endpoints: 13 to 5
- Study sites: 8 to 6
- Interventions: ASP7317 (Drug), Placebo (Other), mycophenolate mofetil (MMF) (Drug), tacrolimus (Drug) to ASP7317 (Drug), tacrolimus (Drug)
- Secondary endpoints: 6 to 4
- Study description shortened, about 24 words
- Study arms: 6 to 2
- Study title expanded, about 2 words
- Minor Study sites: 10 to 8v21
- Notable Primary and study completion dates pushed to Jan 2027v19
- Minor Trial status: Recruiting to Active, Not Recruiting
- Study description expanded, about 9 words
- Site details revised at 10 of 10 sites
- Minor Study description shortened, about 315 words
- Study title shortened, about 4 words
- Minor Study description expanded, about 21 wordsv15
- Minor Site details revised at 1 of 10 sitesv14
- Minor Study sites: 9 to 10v13
- Minor Study sites: 8 to 9v12
- Notable Eligibility criteria shortened, about 345 words
- Primary endpoints revised (13)
- Secondary endpoints: details revised at 1 of 6 entries
- Minor Study sites: 5 to 8v10
- Minor Study sites: 4 to 5v9
- Minor Study sites: 3 to 4v8
- Notable Eligibility criteria shortened, about 5 words
- Study sites: 2 to 3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 2
- Start date changed from estimate of Dec 2018 to Jul 13, 2018
- Notable Start date: Mar 2018 to Dec 2018v4
- Notable Eligibility criteria expanded, about 87 words
- Primary endpoints: 6 to 13
- Secondary endpoints: 4 to 6
- Study description expanded, about 21 words
- Notable Primary completion date: Aug 31, 2020 to Apr 2021
- Start date: Aug 21, 2017 to Mar 2018
- Study completion date: Feb 28, 2026 to Oct 2026
- Interventions: ASP7317 (Drug), Placebo (Other), Prograf® (Drug), mycophenolate mofetil (MMF) (Drug) to ASP7317 (Drug), Placebo (Other), mycophenolate mofetil (MMF) (Drug), tacrolimus (Drug)
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (12)
Show 7 moreShow less
Arms and interventions
Successive cohorts of participants (3 participants each) will be given escalating doses (cohort 1: low cells/dose; cohort 2: medium cells/dose; cohort 3: high cells/dose). Optional Expansion cohorts 3b will be opened after cohort 3 has been filled and 2b will be opened only if necessary. Dose levels for the expansion cohort will align with dose levels in escalation cohorts. Sentinel dosing will be required for each dose level. After the first participant in each dose cohort in Group 1 is dosed and followed for 4 weeks, the Independent Data Monitoring Committee (IDMC) will review the 4-week safety data and recommend if the second and third participants in Group 1 dose cohort may be treated. The IDMC recommendation to progress to the next dosing cohort will be based on 4-week follow-up safety review of the second and third participants in the preceding dose cohort. Participants will receive tacrolimus and other medicines to stop infection.
Successive cohorts of participants (3 participants each) will be given escalating doses (cohort 4: low cells/dose; cohort 5: medium cells/dose; cohort 6: high cells/dose). Optional Expansion cohorts 5b and 6b will be opened after cohorts 5 and 6 have been filled. Dose levels for the expansion cohorts will align with dose levels in escalation cohorts. Cohort 4 (low cells/dose) dosing may begin after the IDMC recommendation to begin dosing in Group 1 cohort 2 (medium cells/dose). Cohort 5 (medium cells/dose) dosing may begin after IDMC review of the 4- week safety data of the first participant in Group 1 cohort 2 (medium cells/dose). Cohort 6 (high cells/dose) dosing may begin after IDMC review of 4-week safety data of the first participant in Group 1 cohort 3 (high cells/dose). Dosing in cohort 5 and 6 can only begin after the IDMC review and the completion of the preceding cohort. Participants will receive tacrolimus and other medicines to stop infection.
Drugs: ASP7317, tacrolimus, trimethoprim-sulfamethoxazole, Acyclovir, Nystatin
Sites
20 sites in 1 country